Medication info

Bonvinal Injection (Ibandronate Sodium Monohydrate)

Prescription medicationInjections
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
This is an injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use needle attached.
Packaging
3 ml x 1 vial
Approval status
Active

MFDS item code 201908101 · Notified 2019.11.26

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who uses it
Adults · Children
Adult dosage
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a scheduled dose is missed, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min; use of this medicine is not recommended in these patients. Elderly No dose adjustment is necessary.
Children's dosage
Efficacy and safety in children 18 years or younger have not been studied.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

It is used for the treatment of osteoporosis in postmenopausal women. This medication increases bone density, strengthens bones, and reduces the risk of fractures. It also helps prevent bone loss and improve bone health.

Dosage and Administration

Adult dosage

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a scheduled dose is missed, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min; use of this medicine is not recommended in these patients. Elderly No dose adjustment is necessary.

Children's dosage

Efficacy and safety in children 18 years or younger have not been studied.

Precautions

This medication must be administered intravenously, and caution should be taken as administration into arteries or around veins may damage surrounding tissues. It should not be used in individuals allergic to this medication or its components. Additionally, it should not be administered to patients with hypocalcemia, a condition of low calcium levels in the blood. This medication may cause gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation. Musculoskeletal symptoms such as musculoskeletal pain, joint pain, and myalgia have also been reported. In some patients, systemic and neurological adverse reactions may occur, such as flu-like symptoms, fatigue, headache, and rash. Rarely, severe allergic reactions such as skin allergy reactions, angioedema, and anaphylaxis may occur; if symptoms arise, immediate consultation with a healthcare professional is necessary. This medication may temporarily lower serum calcium levels, so treatment for hypocalcemia or bone and mineral metabolism disorders should be performed prior, and it is important to ensure adequate intake of calcium and vitamin D. Patients undergoing dental treatment or cancer patients may be at risk for osteonecrosis of the jaw, so oral examinations and preventive dental treatments are necessary before using this medication. Excessive dental treatment should be avoided while administering the medication, and if osteonecrosis of the jaw is suspected, consultation with a specialist is required. In some patients receiving this medication, fractures may occur in uncommon sites such as the femur, so if pain occurs in the thigh or groin area, an evaluation should be conducted. The safety in pregnant or breastfeeding women has not been established; therefore, its use is not recommended. This medication is not metabolized in the liver and is excreted through the kidneys; hence, patients with impaired kidney function need regular monitoring during treatment. In cases of overdose, kidney and liver function should be carefully monitored, and appropriate treatment should be provided if electrolyte imbalances such as hypocalcemia occur. This medication should not be mixed with calcium-containing solutions and must be administered exclusively via intravenous injection. After use, the injection needle and syringe should not be reused and must be disposed of safely.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • indigestion
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illness
Show 54 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • asthma exacerbation
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical electronic fracture
  • intertrochanteric femoral fracture
  • external auditory canal osteonecrosis
  • osteonecrosis of the jaw
  • acute renal failure
  • sensory decrease
  • dizziness
  • optic atrophy
  • lower motor neuron lesions
  • tremors
  • unspecified gastrointestinal disorders
  • benign gastrointestinal neoplasm
  • toothache
  • hyperventilation
  • cough
  • dyspnea
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • multiple organ dysfunction
  • death
  • insomnia
  • anxiety
  • tinnitus
  • hearing loss
  • hypothyroidism
  • lipoma
  • ocular hemorrhage
  • heart failure
  • urinary disorders
  • hematuria
  • skin desquamation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air exposure and should be kept at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication and prevents degradation.

Appearance and packaging

Appearance

This is an injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use needle attached.

Package unit

3 ml x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.